| MeSH term | MeSH ID | Detail |
|---|---|---|
| Connective Tissue Diseases | D003240 | 2 associated lipids |
| Corneal Diseases | D003316 | 13 associated lipids |
| Cough | D003371 | 19 associated lipids |
| Crigler-Najjar Syndrome | D003414 | 1 associated lipids |
| Crohn Disease | D003424 | 12 associated lipids |
| Cryptococcosis | D003453 | 3 associated lipids |
| Cutis Laxa | D003483 | 1 associated lipids |
| Cystic Fibrosis | D003550 | 65 associated lipids |
| Cystitis | D003556 | 23 associated lipids |
| Phyllodes Tumor | D003557 | 1 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Mueller AR et al. | Severe neurotoxicity after liver transplantation: association between FK 506 therapy and hepatitis C virus disease. | 1994 | Transplant. Proc. | pmid:7527951 |
| Tai J et al. | In vivo function of pig islet xenografts in immunosuppressed diabetic mice. | 1995 | Transplant. Proc. | pmid:8539968 |
| Schreier MH et al. | Inhibition of T-cell signaling pathways by immunophilin drug complexes: are side effects inherent to immunosuppressive properties? | 1993 | Transplant. Proc. | pmid:7679818 |
| Tze WJ et al. | Immunohistochemical studies of pig islet xenograft in rats immunosuppressed with FK 506. | 1994 | Transplant. Proc. | pmid:7513470 |
| Zheng B et al. | Effects of the new and highly active immunosuppressant, rapamycin, on lymphoid tissues and cells in vivo. | 1991 | Transplant. Proc. | pmid:1703717 |
| Todo S et al. | Early trials with FK 506 as primary treatment in liver transplantation. | 1990 | Transplant. Proc. | pmid:1689886 |
| Samuel D et al. | Tacrolimus (FK506)-based dual versus triple therapy following liver transplantation. | 1998 | Transplant. Proc. | pmid:9636563 |
| Goto Y et al. | Outcome of tacrolimus-treated renal transplantation from elderly donors. | 2000 | Transplant. Proc. | pmid:11119908 |
| McDiarmid S et al. | One hundred children treated with tacrolimus after primary orthotopic liver transplantation. | 1998 | Transplant. Proc. | pmid:9636564 |
| Toda F et al. | Non-heart-beating donor kidney transplantation under tacrolimus immunosuppression. | 2000 | Transplant. Proc. | pmid:11119909 |
| Chang HY et al. | Long-term follow-up of arrhythmia characteristics and clinical outcomes in heart transplant patients. | 2013 Jan-Feb | Transplant. Proc. | pmid:23375324 |
| Matevossian E et al. | Liver transplantation in the rat: single-center experience with technique, long-term survival, and functional and histologic findings. | 2009 Jul-Aug | Transplant. Proc. | pmid:19715990 |
| Videla CO | Two-year experience with tacrolimus in renal transplantation after late conversion from cyclosporine therapy. | 2009 Jul-Aug | Transplant. Proc. | pmid:19715995 |
| Müller H et al. | Immunosuppression with generic tacrolimus and mycophenolate mofetil in renal transplant recipients: preliminary report in Chile. | 2008 | Transplant. Proc. | pmid:18454992 |
| Reyes J et al. | Nutritional management of intestinal transplant recipients. | 1993 | Transplant. Proc. | pmid:7680149 |
| Abu-Elmagd KM et al. | Monitoring and treatment of intestinal allograft rejection in humans. | 1993 | Transplant. Proc. | pmid:7680150 |
| Farghali H et al. | A biochemical and 31P-NMR investigation of the effect of FK 506 and cyclosporine pretreatment on immobilized hepatocytes perifused with ethanol. | 1991 | Transplant. Proc. | pmid:1721284 |
| Pirenne J et al. | Addition of the colon to small bowel grafts causes lethal graft-versus-host disease in FK 506-treated pigs. | 1996 | Transplant. Proc. | pmid:8623447 |
| Harrison DM et al. | Reduction in hospital stay after liver transplantation. | 1996 | Transplant. Proc. | pmid:8623451 |
| de la Fuente S et al. | Long-term survivors after pediatric liver transplatation are at increased risk for development of cardiovascular disease events: analysis of 30 cases. | 2014 | Transplant. Proc. | pmid:25420837 |
| Walker S et al. | Clinical use and bioavailability of tacrolimus in heart-lung and double lung transplant recipients with cystic fibrosis. | 1998 | Transplant. Proc. | pmid:9636618 |
| Watanabe K et al. | Donor bone marrow cell infusion is effective in inducing tolerance in dogs treated with fractionated lymphoid irradiation and FK506. | 2000 | Transplant. Proc. | pmid:11120286 |
| Perrella A et al. | Cytomegalovirus infection after liver transplantation: prophylaxis and preemptive treatment--a single-center experience. | 2010 | Transplant. Proc. | pmid:20534267 |
| Meçule A et al. | Once daily tacrolimus formulation: monitoring of plasma levels, graft function, and cardiovascular risk factors. | 2010 | Transplant. Proc. | pmid:20534290 |
| Alloway R et al. | Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen. | 2005 | Transplant. Proc. | pmid:15848559 |
| Tellis V et al. | No-load sirolimus with tacrolimus and steroids is safe and effective in renal transplantation. | 2005 | Transplant. Proc. | pmid:15848571 |
| Chen JS et al. | Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus. | 2009 | Transplant. Proc. | pmid:19545678 |
| Akbas SH et al. | Evaluation of the new EMIT tacrolimus assay in kidney and liver transplant recipients. | 2004 Jan-Feb | Transplant. Proc. | pmid:15013308 |
| Bakar F et al. | Low-density lipoprotein oxidizability and the alteration of its fatty acid content in renal transplant recipients treated with cyclosporine/tacrolimus. | 2009 | Transplant. Proc. | pmid:19545695 |
| Cabello M et al. | Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. | 2010 | Transplant. Proc. | pmid:20970603 |
| Marcén R et al. | Effects of the new immunosuppressive agents on the occurrence of malignancies after renal transplantation. | 2010 | Transplant. Proc. | pmid:20970609 |
| Nardo B et al. | Pretransplant xenogeneic blood transfusion combined with FK 506 prolongs hamster-to-rat liver xenograft survival. | 1994 | Transplant. Proc. | pmid:7518112 |
| Pan F et al. | FK 506 prolongs survival of liver but not heart mouse-to-rat vascularized xenografts. | 1994 | Transplant. Proc. | pmid:7518113 |
| Wiesner RH et al. | Early cellular rejection treated with high-dose intravenous corticosteroid therapy is associated with a decrease in the incidence of steroid-resistant rejection and graft failure from rejection. | 1993 | Transplant. Proc. | pmid:7682352 |
| Bäckman L et al. | Whole-blood and plasma levels of FK 506 after liver transplantation: results from the US Multicenter Trial. FK506 Multicenter Study Group. | 1995 | Transplant. Proc. | pmid:7533361 |
| Frank B et al. | Neurotoxicity of FK 506 in liver transplant recipients. | 1993 | Transplant. Proc. | pmid:7682355 |
| Söderdahl G et al. | FK 506 improves recovery of bile secretion following orthotopic liver transplantation in man. | 1995 | Transplant. Proc. | pmid:7533362 |
| Zeevi A et al. | Comparative in vitro studies on the immunosuppressive activities of mycophenolic acid, bredinin, FK 506, cyclosporine, and rapamycin. | 1991 | Transplant. Proc. | pmid:1721315 |
| Matsuura T et al. | Beneficial immunosuppressive effect of combined use of FK 506 and cyclosporine assessed by proliferative responses of cloned human T cells. | 1991 | Transplant. Proc. | pmid:1721316 |
| Erickson L et al. | Gene expression profiling of acute rejection and mixed lymphocyte reaction with tacrolimus immunosuppression. | 2002 | Transplant. Proc. | pmid:12176407 |
| Wynn C et al. | High level of TGF-beta in organ transplantation might be due to rejection rather than calcineurin inhibitor medication. | 2002 | Transplant. Proc. | pmid:12176408 |
| Mizuta K et al. | Increase of bile acid production by tacrolimus in the rat liver. | 2003 | Transplant. Proc. | pmid:12591477 |
| van Hooff JP and Christiaans MH | Use of tacrolimus in renal transplantation. | 1999 | Transplant. Proc. | pmid:10616483 |
| Loucaidou M et al. | Cytokine polymorphisms do not influence acute rejection in renal transplantation under tacrolimus-based immunosuppression. | 2005 | Transplant. Proc. | pmid:15919456 |
| Ping X et al. | Antigen sampling on the Peyer's patches in a murine small bowel transplantation model. | 2010 | Transplant. Proc. | pmid:21094860 |
| Bismuth H | Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group. | 1995 | Transplant. Proc. | pmid:7533415 |
| Jain AB et al. | Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant. | 1991 | Transplant. Proc. | pmid:1721347 |
| Weis M et al. | Impact of immunosuppression on coronary endothelial function after cardiac transplantation. | 1998 | Transplant. Proc. | pmid:9595131 |
| Pascual J et al. | Comparison between a two-drug regimen with tacrolimus and steroids and a triple one with azathioprine in kidney transplantation: results of a European trial with 3-year follow up. | 2003 | Transplant. Proc. | pmid:12962764 |
| Urbizu JM et al. | Safety and efficacy of tacrolimus rescue therapy in 55 kidney transplant patients treated with cyclosporine. | 2003 | Transplant. Proc. | pmid:12962765 |
| Lyne JC et al. | Cadaveric renal transplantation against a positive historic crossmatch under tacrolimus immunosuppression: long-term follow-up. | 1997 Feb-Mar | Transplant. Proc. | pmid:9123015 |
| Zucker K et al. | Augmentation of mycophenolate mofetil pharmacokinetics in renal transplant patients receiving Prograf and CellCept in combination therapy. | 1997 Feb-Mar | Transplant. Proc. | pmid:9123027 |
| Sugitani A et al. | Intestinal neurons in acute and chronic rejection after small bowel transplantation in dogs. | 1996 | Transplant. Proc. | pmid:8907941 |
| Charpentier B | A three arm study comparing immediate tacrolimus therapy with ATG induction therapy followed by either tacrolimus or cyclosporine in adult renal transplant recipients. | 2002 | Transplant. Proc. | pmid:12176511 |
| Ronchetti F et al. | Mucosal hyaluronic acid quantification in small bowel transplantation in pigs. | 1996 | Transplant. Proc. | pmid:8907950 |
| Montagnino G et al. | Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in kidney transplantation: twelve-month follow-up. | 2002 | Transplant. Proc. | pmid:12176515 |
| Borda B et al. | Functional and histopathologic changes in renal transplant patients with new-onset diabetes and dyslipidemia. | 2011 | Transplant. Proc. | pmid:21620104 |
| Takahara S et al. | Monitoring of FK 506 blood levels in kidney transplant recipients. | 1994 | Transplant. Proc. | pmid:7520623 |
| Sun CK et al. | Intensive care after orthotopic liver transplantation. | 1994 | Transplant. Proc. | pmid:7520627 |
| Wagner K et al. | Effect of FK 506 on excretion of urinary enzymes in rats. | 1991 | Transplant. Proc. | pmid:1721379 |
| Warty V et al. | Distribution of FK 506 in plasma lipoproteins in transplant patients. | 1991 | Transplant. Proc. | pmid:1703363 |
| Prasad SJ et al. | In vitro effects of cyclosporine and FK 506 on the renal cortex. | 1991 | Transplant. Proc. | pmid:1721380 |
| Kusne S et al. | Early infections in kidney transplant recipients under FK 506. | 1991 | Transplant. Proc. | pmid:1703364 |
| Krzyżowska K et al. | No Significant Influence of Reduced Initial Tacrolimus Dose on Risk of Underdosing and Early Graft Function in Older and Overweight Kidney Transplant Recipients. | Transplant. Proc. | pmid:30056895 | |
| Kim K et al. | Everolimus-Induced Systemic Serositis After Simultaneous Liver and Kidney Transplantation: A Case Report. | Transplant. Proc. | pmid:28104132 | |
| Weir M | Impact of immunosuppressive regimes on posttransplant diabetes mellitus. | 2001 | Transplant. Proc. | pmid:11498201 |
| Kaibori M et al. | Inhibition of iNOS induction by FK506, but not by cyclosporine, in rat hepatocytes. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083347 |
| Lee S et al. | Mycophenolic acid trough level measurements and clinical outcomes in kidney transplantation recipients on a fixed dose (1.5 g/d) of mycophenolate mofetil in Korea. | 2010 | Transplant. Proc. | pmid:20430174 |
| el-Ghoroury M et al. | Efficacy and safety of tacrolimus versus cyclosporine in kidney and pancreas transplant recipients. | 1997 Feb-Mar | Transplant. Proc. | pmid:9123461 |
| Ali IH et al. | Incidence and risk factors for post-renal transplant diabetes mellitus. | 2011 | Transplant. Proc. | pmid:21440763 |
| McGrath JS and Shehata M | Chronic allograft nephropathy: prospective randomised trial of cyclosporin withdrawal and mycophenolate mofetil or tacrolimus substitution. | 2001 | Transplant. Proc. | pmid:11377500 |
| Mueller AR et al. | Long-term follow-up in hepatitis C patients with respect to immunosuppression. | 1996 | Transplant. Proc. | pmid:8962255 |
| Baid S et al. | Tacrolimus-associated posttransplant diabetes mellitus in renal transplant recipients: role of hepatitis C infection. | 2002 | Transplant. Proc. | pmid:12176569 |
| Ricordi C et al. | Human islet allotransplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1721410 |
| Stütz A | Immunosuppressive macrolides. | 1992 | Transplant. Proc. | pmid:1379762 |
| Harihara Y et al. | Effects of interferon alpha/beta on cardiac allografts. | 1996 | Transplant. Proc. | pmid:8658645 |
| Beck Y and Akiyama N | Effect of FK-506 and cyclosporine on human lymphocyte responses in vitro. | 1989 | Transplant. Proc. | pmid:2472695 |
| Cai W et al. | Limited Sampling Strategy for Estimating Mycophenolic Acid Exposure on Day 7 Post-Transplant for Two Mycophenolate Mofetil Formulations Derived From 20 Chinese Renal Transplant Recipients. | 2018 | Transplant. Proc. | pmid:29735215 |
| Abouljoud M et al. | Conversion to neoral provides effective rescue therapy for liver and kidney transplant patients intolerant of Prograf. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267175 |
| Kauffman HM et al. | Drug regimens affect cadaveric kidney graft survival. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267176 |
| Zhang J et al. | Chemotherapy for De Novo Gastric Adenocarcinoma After Deceased Orthotopic Liver Transplantation: A Case Report. | Transplant. Proc. | pmid:28104131 | |
| Berweck S et al. | Clinical use of the euglycemic hyperinsulinemic clamp for diagnosis of tacrolimus-induced insulin resistance after combined pancreas-kidney transplantation. | 1998 | Transplant. Proc. | pmid:9723345 |
| Ettenger RB | New immunosuppressive agents in pediatric renal transplantation. | 1998 | Transplant. Proc. | pmid:9723350 |
| Neff GW et al. | Ten years of sirolimus therapy in orthotopic liver transplant recipients. | 2003 | Transplant. Proc. | pmid:12742498 |
| Petz W et al. | Experience with the use of basiliximab in liver transplantation--use in pediatric and adult recipients in combination with cyclosporine or tacrolimus. | 2002 | Transplant. Proc. | pmid:12176648 |
| Yokomise H et al. | Immunosuppressive effects of FK 506 in canine lung transplantation. | 1991 | Transplant. Proc. | pmid:1721442 |
| McCauley J et al. | Renal transplantation under FK 506 in African-Americans: early experience. | 1993 | Transplant. Proc. | pmid:7689270 |
| Ochiai T et al. | Histopathologic studies in renal transplant recipient dogs receiving treatment with FK-506. | 1987 | Transplant. Proc. | pmid:2445085 |
| Groetzner J et al. | Tacrolimus or cyclosporine for immunosuppression after cardiac transplantation: which treatment reveals more side effects during long-term follow-up? | 2001 Feb-Mar | Transplant. Proc. | pmid:11267373 |
| Pretagostini R et al. | Delayed Introduction of Everolimus in De Novo Renal Transplanted Patients: A Single-Center Experience. | 2016 | Transplant. Proc. | pmid:27109947 |
| Chávez R et al. | Hepatotrophic effect of cyclosporine and FK 506 is not mimicked by rapamycin. | 1999 | Transplant. Proc. | pmid:10500655 |
| Ginevri F et al. | Expression of collagen by renal fibroblasts treated with FK 506 in vitro. | 1998 | Transplant. Proc. | pmid:9636387 |
| Hutchinson IV et al. | Differences in the mode of action of cyclosporine and FK 506. | 1998 | Transplant. Proc. | pmid:9636388 |
| Dall'Agnol DJ et al. | Effects of immunosuppressive drugs on gastrointestinal transit of rats: effects of tacrolimus, cyclosporine, and prednisone. | Transplant. Proc. | pmid:25131057 | |
| Iwata H et al. | Prolongation of xenograft survival by combining donor-specific intravenous presensitization with FK 506. | 2002 | Transplant. Proc. | pmid:12431592 |
| Itagaki F et al. | Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation. | 2002 | Transplant. Proc. | pmid:12431607 |
| Rong G et al. | Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients. | 2010 | Transplant. Proc. | pmid:21094796 |
| Zhang J et al. | Value of CYP3A5 genotyping on determining initial dosages of tacrolimus for Chinese renal transplant recipients. | 2010 | Transplant. Proc. | pmid:21094797 |
| van Hooff JP et al. | Preservation of renal function and cardiovascular risk factors. | 2006 | Transplant. Proc. | pmid:16979974 |
| Carl S et al. | Combining FK 506 and mycophenolate mofetil for the treatment of acute corticosteroid-resistant rejection following kidney transplantation: a new therapeutic concept. | 1998 | Transplant. Proc. | pmid:9636502 |